Skip to content
Axcess News – Lifestyle
Author:
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
March 5, 2026
←
Previous Page
1
2